Drug intelligence / Profile preview

SC401B

Development stage: Discontinued
Lead developer: Sancilio & Co.
Modality: Small Molecules
Administration: Oral

Overview

**SC401B** is an investigational oral omega-3-acid ethyl ester product developed by Sancilio for severe hypertriglyceridemia. It contains ethyl esters of eicosapentaenoic acid and docosahexaenoic acid, together with surfactants intended to improve absorption in both fasted and fed states. In a registered Phase 3 trial, SC401B was evaluated at daily doses of two, four, or six capsules for lowering triglycerides in people with baseline triglyceride concentrations of 500 to 2,000 mg/dL; the study was withdrawn.

Other names: EPA+DHAeicosapentaenoic acid ethyl ester + docosahexaenoic acid ethyl ester

Targets

PPARA (Peroxisome proliferator-activated receptor alpha)DGAT1 (Diacylglycerol O-acyltransferase 1)SREBP-1 / SREBF1 (SREBP-1)

Beyond the preview

Go deeper on SC401B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SC401B.

Explore the full profile